9.58
+0.81(+9.24%)
Currency In USD
Address
345 Park Avenue South
New York City, 10010
United States of America
Phone
212-547-9879
Website
Sector
Healthcare
Industry
Biotechnology
Employees
75
First IPO Date
November 03, 2023
| Name | Title | Pay | Year Born |
| Mr. R. Nolan Townsend | Chief Executive Officer & Director | 3.74M | 1981 |
| Ms. Jenny R. Robertson J.D. | Chief Legal Officer | 617,900 | 1975 |
| Dr. Eric Adler M.D. | Chief Medical Officer & Head of Research | 2.71M | 1974 |
| Dr. Jose Manuel Otero Ph.D. | Chief Technical Officer | 2.99M | 1979 |
| Mr. Jordan M. Baumhardt Ph.D. | Vice President of Corporate Development | 0 | N/A |
| Dr. Kyle Rasbach Ph.D., Pharm.D. | Chief Financial Officer | 0 | 1980 |
| Mr. Ryan McHenry | Vice President & Corporate Controller | 0 | N/A |
| Dr. Sandi See Tai M.D. | Chief Development Officer | 0 | 1971 |
| Dr. Ronald G. Crystal M.D. | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board | 0 | N/A |
| Ms. Leslie DiRisio | Senior Vice President of Development Operations | 0 | N/A |
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.